We are live on ! Find out more
SNDX icon

Syndax Pharmaceuticals
SNDX

139 hedge funds and large institutions have $1.39B invested in Syndax Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 61 increasing their positions, 27 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,129% more call options, than puts

Call options by funds: $5.43M | Put options by funds: $442K

150% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 12

126% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 27

67% more funds holding in top 10

Funds holding in top 10: 6 → 10 (+4)

37% more capital invested

Capital invested by funds: $1.02B → $1.39B (+$373M)

15% more funds holding

Funds holding: 121 → 139 (+18)

7.66% more ownership

Funds ownership: 98.21% → 105.87% (+7.7%)

Holders
139
Holders Change
+18
Holders Change %
+14.88%
% of All Funds
2.39%
Holding in Top 10
10
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+66.67%
% of All Funds
0.17%
New
30
Increased
61
Reduced
27
Closed
12
Calls
$5.43M
Puts
$442K
Net Calls
+$4.99M
Net Calls Change
+$1.53M

Top Buyers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
+$37M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$26.5M
3
WP
Woodline Partners
California
+$17.7M
4
CC
Commodore Capital
New York
+$16.6M
5
PHS
PFM Health Sciences
California
+$15.9M

Top Sellers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
-$28.9M
2
DM
Deerfield Management
New York
-$21.4M
3
BI
BVF Inc
California
-$12.5M
4
6CM
683 Capital Management
New York
-$10.1M
5
PF
Phoenix Financial
Israel
-$10.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
FCMI
26
Foresite Capital Management IV
California
$16.6M +$15.5M +690,000 New
JP Morgan Chase
27
JP Morgan Chase
New York
$14.8M +$492K +21,949 +4%
PAI
28
Palo Alto Investors
California
$14.7M – – –
Goldman Sachs
29
Goldman Sachs
New York
$13.7M +$490K +21,842 +4%
Citigroup
30
Citigroup
New York
$12.8M +$1.5M +67,007 +14%
SI
31
Sofinnova Investments
California
$12.6M +$2.5M +111,574 +27%
Northern Trust
32
Northern Trust
Illinois
$12.1M +$360K +16,049 +3%
Charles Schwab
33
Charles Schwab
California
$9.26M +$633K +28,216 +8%
Two Sigma Advisers
34
Two Sigma Advisers
New York
$8.93M +$424K +18,900 +5%
DCM
35
DAFNA Capital Management
California
$8.54M -$348K -15,500 -4%
Lord, Abbett & Co
36
Lord, Abbett & Co
New Jersey
$8.05M +$450K +20,049 +6%
ACP
37
Acuta Capital Partners
California
$7.8M +$2.68M +119,611 +58%
Bank of America
38
Bank of America
North Carolina
$7.26M +$5.08M +226,494 +299%
UBS Group
39
UBS Group
Switzerland
$6.86M -$699K -31,143 -10%
Ameriprise
40
Ameriprise
Minnesota
$6.65M +$6.21M +276,731 New
Barclays
41
Barclays
United Kingdom
$6.63M +$6.08M +271,168 +5,907%
Ensign Peak Advisors
42
Ensign Peak Advisors
Utah
$5.08M +$1.91M +85,177 +67%
GTC
43
Ghost Tree Capital
New York
$4.81M -$561K -25,000 -11%
Bank of New York Mellon
44
Bank of New York Mellon
New York
$4.55M +$494K +22,007 +13%
Norges Bank
45
Norges Bank
Norway
$4.52M +$4.22M +188,200 New
Macquarie Group
46
Macquarie Group
Australia
$4.35M -$22.2K -991 -0.5%
N
47
Nuveen
North Carolina
$3.99M +$785 +35 +0%
Fidelity Investments
48
Fidelity Investments
Massachusetts
$3.99M +$902K +40,217 +32%
Morgan Stanley
49
Morgan Stanley
New York
$3.81M -$2.99M -133,106 -46%
Rafferty Asset Management
50
Rafferty Asset Management
New York
$3.52M +$1.54M +68,478 +88%
1
2
3 4 5

SNDX Hedge Fund Activity: Q3 2022 in Review

139 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q3 2022, worth a combined $1.39B — up 37% from $1.02B a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new SNDX positions and 12 closed out — a net gain of 18 holders — while 61 added to existing stakes and 27 trimmed.

The largest buyer was Jennison Associates, opening a new position worth an estimated $37M. The largest seller was Nantahala Capital Management, cutting an estimated $28.9M.

  • 139 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q3 2022, up from 121 in Q2 2022.
  • Funds reported $1.39B of Syndax Pharmaceuticals stock for Q3 2022, up 37% quarter-over-quarter.
  • 30 funds opened new Syndax Pharmaceuticals positions in Q3 2022 and 12 closed out, a net change of +18 holders.
  • The largest Syndax Pharmaceuticals buyer in Q3 2022 was Jennison Associates, an estimated $37M added.
  • The largest Syndax Pharmaceuticals seller in Q3 2022 was Nantahala Capital Management, an estimated $28.9M sold.

Based on aggregated 13F filings for Q3 2022.